
METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with
METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with
We met Emma as she applied to be one of the METUPUK Darker Side of Pink ladies with our campaign that started in 2021 which focused on metastatic breast cancer,
Back in the summer of 2022, our daughter’s partner, Bren, talked to me about the IN NAM Graduate Desert challenge that he had signed up to. When he explained what
As a partner of someone with metastatic cancer, it can be very difficult to know what the right amount of paid work is to do. Sometimes it feels like I
Do you remember what you were wearing on 1 December 2019? Probably not. I do though. I was wearing a blue Valencia Marathon t-shirt, an exhausted but elated perma-grin and
Clinical trials are essential for testing new treatments for metastatic breast cancer. For patients, they represent hope – the chance to get access to a new potential treatment before it
Starting a new medication can be a daunting experience, especially if the medication is still fairly new to the market. Abemaciclib may not be a household name, but for those
Tassia Haines – METUPUK (Wales) member, patient advocate & fantastic artist. Back in February, I had to go into hospital after side effects from being on Trodelvy. I wanted